LYSARC (Lymphoma Studies Academic Research Company) was founded in 2012 following the merger of two leading academic groups (GELA and GOELAMS) who decided to combine their clinical experience, methodological expertise and access to patients. This merger created a world-class specialist research organization in the field of lymphoma. LYSARC objective is to improve the access of innovative therapies for lymphoma patients. LYSARC is a nonprofit trust governed by an independent Board composed of leading clinicians and pathologists with international reputation in the field of lymphoma research. For each trial, you will find the acronym, title of trial, population, trials details, inclusion and exclusion criteria.